Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents
Oncological diseases are one of the leading causes of mortality in the world. Despite the intensive search for new methods to increase the efficacy and safety of antineoplastic therapy and to reduce resistance to it by malignant tumors, treatment issues still remain unresolved in clinical oncology....
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2025-05-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/13224 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849327339124555776 |
|---|---|
| author | E. R. Radkevich A. S. Severina M. S. Shamkhalova M. V. Shestakova |
| author_facet | E. R. Radkevich A. S. Severina M. S. Shamkhalova M. V. Shestakova |
| author_sort | E. R. Radkevich |
| collection | DOAJ |
| description | Oncological diseases are one of the leading causes of mortality in the world. Despite the intensive search for new methods to increase the efficacy and safety of antineoplastic therapy and to reduce resistance to it by malignant tumors, treatment issues still remain unresolved in clinical oncology. This review analyses experimental data on the antineoplastic effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors: the reasons why SGLT2 inhibitors can be used for the treatment of malignant tumors are presented, class-specificity and dose-dependence of the antineoplastic effect of the drugs are determined. Possible mechanisms of antitumor effect of glyflozins are described in detail, among which, in addition to reduction of glucose entry into tumor cells, inhibition of Wnt/β-catenin signalling pathway, enhancement of AMP activated protein kinase activity with subsequent change of lipid profile of tumor cells and inhibition of mTOR protein kinase (mammalian target of rapamycin), disruption of DNA and RNA synthesis in malignant tumor cells, etc. play a significant role. Considerable space is devoted to the pro-oncogenic effect of SGLT2 inhibitors, previously undisputed and now disproved, as well as to the interaction of this class of antidiabetic agents with other antitumor treatment in the context of efficacy, safety and therapeutic resistance. |
| format | Article |
| id | doaj-art-7eaca4de9a38453f98bfc8b7ca61c25f |
| institution | Kabale University |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-7eaca4de9a38453f98bfc8b7ca61c25f2025-08-20T03:47:54ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782025-05-0128224325110.14341/DM1322411136Sodium-glucose cotransporter 2 inhibitors as potential anticancer agentsE. R. Radkevich0A. S. Severina1M. S. Shamkhalova2M. V. Shestakova3Endocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreOncological diseases are one of the leading causes of mortality in the world. Despite the intensive search for new methods to increase the efficacy and safety of antineoplastic therapy and to reduce resistance to it by malignant tumors, treatment issues still remain unresolved in clinical oncology. This review analyses experimental data on the antineoplastic effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors: the reasons why SGLT2 inhibitors can be used for the treatment of malignant tumors are presented, class-specificity and dose-dependence of the antineoplastic effect of the drugs are determined. Possible mechanisms of antitumor effect of glyflozins are described in detail, among which, in addition to reduction of glucose entry into tumor cells, inhibition of Wnt/β-catenin signalling pathway, enhancement of AMP activated protein kinase activity with subsequent change of lipid profile of tumor cells and inhibition of mTOR protein kinase (mammalian target of rapamycin), disruption of DNA and RNA synthesis in malignant tumor cells, etc. play a significant role. Considerable space is devoted to the pro-oncogenic effect of SGLT2 inhibitors, previously undisputed and now disproved, as well as to the interaction of this class of antidiabetic agents with other antitumor treatment in the context of efficacy, safety and therapeutic resistance.https://www.dia-endojournals.ru/jour/article/view/13224cancerantineoplastic therapytype 2 diabetes mellitussugar-lowering drugssodium-glucose cotransporter 2sodium-glucose cotransporter 2 inhibitorsgliflozins |
| spellingShingle | E. R. Radkevich A. S. Severina M. S. Shamkhalova M. V. Shestakova Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents Сахарный диабет cancer antineoplastic therapy type 2 diabetes mellitus sugar-lowering drugs sodium-glucose cotransporter 2 sodium-glucose cotransporter 2 inhibitors gliflozins |
| title | Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents |
| title_full | Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents |
| title_fullStr | Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents |
| title_full_unstemmed | Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents |
| title_short | Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents |
| title_sort | sodium glucose cotransporter 2 inhibitors as potential anticancer agents |
| topic | cancer antineoplastic therapy type 2 diabetes mellitus sugar-lowering drugs sodium-glucose cotransporter 2 sodium-glucose cotransporter 2 inhibitors gliflozins |
| url | https://www.dia-endojournals.ru/jour/article/view/13224 |
| work_keys_str_mv | AT erradkevich sodiumglucosecotransporter2inhibitorsaspotentialanticanceragents AT asseverina sodiumglucosecotransporter2inhibitorsaspotentialanticanceragents AT msshamkhalova sodiumglucosecotransporter2inhibitorsaspotentialanticanceragents AT mvshestakova sodiumglucosecotransporter2inhibitorsaspotentialanticanceragents |